YRYasmin Abdul Rashid

Yasmin Abdul Rashid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yasmin Abdul Rashid has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Induced Perceived Infertility Related to Psychological Distress among Adult Women Receiving Chemotherapy at a Tertiary Care Hospital, Karachi, Pakistan; an Analytical Cross-Sectional Study

    by Mahreen Hirani, Yasmin Rashid, Fauzia Basaria Hasnani, Tazeen Ali

    Globally, many individuals of reproductive age are affected by cancer and may experience perceived infertility because of its treatment. The primary objectives of this study were to estimate the mean score of fertility-related distress and to examine the association between perceived infertility and distress among adult women receiving chemotherapy at a tertiary care hospital in Karachi, Pakistan. The secondary objective was to assess the relationship between fertility-related distress and other associated factors in this population. This was an analytical cross-sectional study conducted at a single private tertiary care teaching hospital in Karachi, Pakistan. A sample size of 137 participants was calculated; however, 150 participants successfully completed the survey. The inclusion criteria comprised female patients aged 18 to 50 years undergoing chemotherapy, with no pre-existing infertility issues. Exclusion criteria included a prior psychiatric diagnosis, history of surgery involving reproductive organs, reproductive organ cancer, pregnancy, and single/unmarried status. Fertility-related distress was assessed using the Fertility Problem Inventory Scale, while associated factors were evaluated through a structured questionnaire. The participants had a mean age of 39.75 ± 6.85 years and demonstrated a mean fertility-related distress score of 79.30 ± 1.30. Multivariable linear regression analysis revealed that women who were not planning to have children (𝛽 = 6.43, 95% CI: 2.21–10.64) and those undergoing radiation therapy (𝛽 = 20.86, 95% CI: 15.77–25.94) were significantly associated with higher distress levels. Perceived infertility was not directly associated with distress. However, a significant interaction was observed between perceived infertility and family status, resulting in a negative effect (𝛽 = −2.5, 95% CI: −4.7 to −0.2). Healthcare providers should proactively address fertility-related concerns and provide timely support to women undergoing cancer treatment. Such interventions may help reduce distress and improve the overall psychological well-being of patients.

  • Open Access

    Metastatic non-small cell lung cancer with BRCA2 mutation—a therapeutic challenge

    by Saad Salim Naviwala, Waqas Ahmed Khan, Daania Shoaib, Taha Nafees, Muzammil Shakeel, Yasmin Abdul Rashid

    Non-small cell lung cancer, specifically adenocarcinoma, is amenable to targeted therapy for genetic alterations. The role of BRCA mutations in pathogenesis and the efficacy of PARP inhibitors in these cases are still unclear. This case involves a 61-year-old male patient with a past history of Hodgkin’s Lymphoma and a heavy smoking history who developed lung adenocarcinoma and was found to have a BRCA2 mutation. Following disease progression on first-line chemotherapy and a detailed case discussion in the multidisciplinary team meeting, second-line Olaparib was started, but the patient's condition worsened rapidly, and he died from the illness. This case highlights the fact that BRCA mutations, though less common, are a potential target that should be explored further. Further large-scale studies are crucial to understanding and improving treatment outcomes for patients with BRCA-mutated NSCLC.

  • Open Access

    Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country

    by Mohammad Ss Naviwala, Waqas A Khan, Adeeba Zaki, Mahnoor Tariq, Faiza Ahmed, Warda Saleem, Munira Moosajee, Yasmin A Rashid

    Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Most patients are diagnosed at an advanced stage, limiting their treatment options. The traditional assessment of liver function using the Child–Pugh score has limitations due to its subjectivity. The albumin-bilirubin (ALBI) grade delivers a more precise evaluation of liver function. This study examines overall survival (OS) in advanced HCC patients treated with first-line systemic therapy and the impact of ALBI grading on these outcomes. A total of 104 patients with advanced HCC treated between January 2017 and December 2023 with one of the three first-line therapy options: Sorafenib, lenvatinib or atezolizumab/bevacizumab were retrospectively analyzed. The Kaplan–Meier method was utilized to examine the survival results, and the log-rank test was employed to evaluate the variations in survival among ALBI grades and therapy types. Cox proportional hazards regression examined the impact of ALBI grading and other covariates on OS, with a significance threshold of p < 0.05 for the multivariable model. The median age of HCC patients was 58.5 years, with 70% males, and a primary etiology of hepatitis C (43%). The median OS and time to progression (TTP) in this cohort were 9 months and 3.25 months. In ALBI grade I patients, the OS was 21 months, while in grade II or III patients, it was just 5 months. Treatment-related side effects necessitated dose reductions in over 84% of patients. Albumin-bilirubin grade, Child–Pugh class, and treatment modifications due to adverse effects were significant predictors of survival. Lenvatinib appears to have better survival outcomes compared to other options. The albumin-bilirubin grading is a useful method for evaluating liver function and forecasting survival rates for individuals with HCC. Our findings support the use of ALBI grading in clinical decision-making for advanced HCC. Naviwala MSS, Tariq M, Ahmed F, et al. Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country. Euroasian J Hepato-Gastroenterol 2024;14(2):251–257.


  • Open Access

    HER2-low breast cancer: A new clinical entity

    by Yasmin Abdul Rashid, Samra Khan, Shagufta Khan

    HER2-positive breast cancers (BC) account for ~15-20% of total BC cases with a poor prognosis. The outlook for these patients has improved drastically with the advent of anti-HER2 targeted treatments.1 According to American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) 2018 guidelines, HER2 is considered positive when it is overexpressed on immunohistochemical (IHC) assay with a score of 3+ or 2+ with gene amplification on in-situ hybridization (ISH) assay while negative when IHC staining is 0, 1+, or 2+ with no gene amplification on ISH.2 This dichotomous classification was recently upended when patients with HER2 2+ unamplified and HER2 1+ tumours were identified as promising targets for new anti-HER2 therapies specifically antibody-drug conjugates (trastuzumab deruxtecan or T-DXd).3,4 Thus, a new classification term “HER2-low” was introduced for these patients.3 This was a major leap in treating patients whose disease is chemo-refractive and HER2-driven. However, the emergence of the HER2-low subgroup poses many challenges regarding its pathological classification and biology in early-stage disease. One of the main concerns in classifying HER2-low tumours is the choice of techniques employed i.e. IHC and ISH. These techniques have only been employed to quantify HER2 overexpression in BC, without distinguishing between low levels and no HER2 expression. This makes it imperative to first develop and validate more sensitive and reliable techniques for classifying HER2-low tumours in clinical settings. Until these new methods are developed, the risk of treating new patients and patients already on anti-HER2 therapies poses a significant challenge to clinicians. Latest GLOBOCAN statistics highlight the critical need to improve BC management practices in countries like Pakistan, where disease burden is high, with more than 30,000 BC cases reported in 2022 alone.5 We reviewed the total number of patients who attended our Breast Oncology clinics in 2022 and re-analysed their HER2 status following the new classification. Based on the available results of 528 patients, 117 (22%) early-stage BC patients now fit the criteria of the HER2-low subgroup with either HR+ or HR- status. This emphasizes the importance of properly monitoring such patients and investigating their disease biology and response to existing therapies. It is currently debatable if HER2-low status in BC constitutes a distinct entity in the early stage and whether it has prognostic value. Treatment strategies for individuals with advanced BC have undergone a significant shift because of the introduction of the unique targetable subgroup of HER2-low BC. ---Continue


  • Open Access

    Chaotic transformation of parotid acinic cell carcinoma to metastatic dedifferentiated high-grade pathology - A rare case with clinical and emotional challenge

    by Faiza Ahmed, Saqib Raza Khan, Tasneem Dawood, Aliha Naeem, Munira Moosajee, Yasmin Abdul Rashid

    Acinic cell carcinoma (AciCC) is a rare entity in which high-grade transformation (HGT), formerly dedifferentiation, is uncommon. This case report presents a rare case of AciCC, with rapid transformation to metastatic high-grade dedifferentiated pathology after initial curative treatment. A 58-year-old woman presented in the medical oncology clinic with a progressive swelling on the right side of her face. Magnetic resonance imaging revealed a 5 × 5 cm lobulated parotid gland lesion, and fine needle aspiration biopsy was consistent with carcinoma. After informed consent, a Modified-Blair incision was given as a standard approach to the right preauricular area under general anaesthesia, and a right superficial parotidectomy with the removal of the tumor and selective lymph node dissection was performed. Histopathology of the resected mass was reported as parotid AciCC. She was given adjuvant radiation therapy. A repeat PET CT scan ten weeks after the completion of her adjuvant radiation treatment showed local disease recurrence as well as multiple pulmonary deposits. A repeat biopsy was reported as DOG-1 positive dedifferentiated (high-grade) acinic cell carcinoma, and she was offered platinum-based palliative systemic chemotherapy. Parotid acinic cell carcinomas with high-grade transformation are rare. This case highlights its critical diagnostic markers, curative and palliative management and long-term follow-up. The transformation of parotid AciCC to high-grade, dedifferentiated pathology is unusual and belligerent. Hence, these tumors need intense treatment with a multimodality approach. Close follow-ups with history and physical examination, along with periodic imaging, should be considered for these patients.

  • Open Access

    Cardiac sarcoma

    by Saqib Raza Khan, Saad Nasir, Muhammad Tariq, Yasmin Abdul Rashid, Adnan Abdul Jabbar

    Introduction and importance: Primary cardiac sarcoma is a rare malignancy with a poor prognosis because of diagnostic delay, therapeutic difficulties, and high metastatic potential. The therapeutic approach includes surgery, chemotherapy, and radiation therapy, alone or in combination. However, there is a lack of evidence to guide the treatment. Case presentation: We present a case of primary cardiac sarcoma. Our patient was presented in the department of emergency medicine (ED) in our institute with shortness of breath on exertion associated with orthopnea. Based on the history and cardiovascular examination, he underwent an echocardiogram, which revealed a sizeable echogenic density in the right ventricular outflow tract. He underwent surgical resection of the cardiac mass via median sternotomy and total cardiopulmonary bypass approach. The patient was eventually diagnosed with primary cardiac sarcoma, confirmed by tissue biopsy after surgical intervention. Clinical discussion: Through this report, we highlight the rarity of primary cardiac sarcomas, the importance of multidisciplinary tumor board (MDT) discussion and provide evidence of surgical excision being the treatment of choice, followed by systemic chemotherapy in selected cases. Conclusion: Cardiac sarcoma is a rare but highly malignant tumor with a poor prognosis. However, early diagnosis and surgical resection of a primary cardiac sarcoma can significantly increase the patient's survival and quality of life. Therefore, physicians should keep a high suspicion of a patient with clinical features suggestive of cardiac sarcoma, and echocardiography should be the diagnostic modality of choice in such patients. Highlights:

  • Open Access

    Abdominal myoepithelial carcinoma: A rare abdominal wall entity of an uncommon tumor

    by Daania Shoaib, Saqib Raza Khan, Yasmin Abdul Rashid, Muhammad Nauman Zahir

    Myoepithelial carcinomas are a diverse group of tumors exhibiting myoepithelial differentiation. There have been increasing reports of extra-salivary sites of origin for myoepithelial carcinomas such as soft tissues, bone and visceral areas. Due to this entity's rarity, definite diagnostic and treatment parameters are somewhat limited. We present the case of a myoepithelial carcinoma arising from the abdominal wall, a rare site of origin of an uncommon tumor. A 37-year-old gentleman presented to our institution in Oct 2018 with a recurrent abdominal mass for which he underwent wide local excision after completing the workup, which included systemic scans and relevant blood investigations. The histopathology report was consistent with malignant abdominal myoepithelial carcinoma. However, subsequent follow-up scans in May 2019 showed disease progression with the appearance of multiple lung metastases. After a detailed discussion, he was started on Pazopanib 800 mg orally once a day, on which he remained stable till May 2022. It was then when he experienced clinical disease progression confirmed on systemic scans, so he was offered palliative systemic chemotherapy. Abdominal malignant myoepithelial carcinomas are an infrequent entity. However, this case highlights its critical diagnostic markers and primary and recurrent abdominal myoepithelial carcinoma management. Abdominal myoepithelial carcinomas, although rare, are also under-recognized. Thus, keeping an index of high suspicion for these tumors and being armed with knowledge regarding the heterogeneity of its features would lead to better diagnostic awareness and documentation, paving the way for better evidence-based treatments.


  • Open Access

    Spectrum of germline pathogenic variants using a targeted next generation sequencing panel and genotype-phenotype correlations in patients with suspected hereditary breast cancer at an academic medical centre in Pakistan

    by Fizza Akbar, Zahraa Siddiqui, Muhammad Talha Waheed, Lubaina Ehsan, Syed Ibaad Ali, Hajra Wiquar, Azmina Tajuddin Valimohammed, Shaista Khan, Lubna Vohra, Sana Zeeshan, et al.

    Background: Breast cancer is the most common malignancy in women, affecting over 1.5 million women every year, which accounts for the highest number of cancer-related deaths in women globally. Hereditary breast cancer (HBC), an important subset of breast cancer, accounts for 5–10% of total cases. However, in Low Middle-Income Countries (LMICs), the population-specific risk of HBC in different ethnicities and the correlation with certain clinical characteristics remain unexplored. Methods: Retrospective chart review of patients who visited the HBC clinic and proceeded with multi-gene panel testing from May 2017 to April 2020. Descriptive and inferential statistics were used to analyze clinical characteristics of patients. Fisher’s exact, Pearson’s chi-squared tests and Logistic regression analysis were used for categorical variables and Wilcoxon rank-sum test were used for quantitative variables. For comparison between two independent groups, Mann-Whitney test was performed. Results were considered significant at a p value of < 0.05. Results: Out of 273 patients, 22% tested positive, 37% had a VUS and 41% had a negative genetic test result. Fifty-five percent of the positive patients had pathogenic variants in either BRCA1 or BRCA2, while the remaining positive results were attributed to other genes. Patients with a positive result had a younger age at diagnosis compared to those having a VUS and a negative result; median age 37.5 years, IQR (Interquartile range) (31.5–48). Additionally, patients with triple negative breast cancer (TNBC) were almost 3 times more likely to have a positive result (OR = 2.79, CI = 1.42–5.48 p = 0.003). Of all patients with positive results, 25% of patients had a negative family history of breast and/or related cancers. Conclusions: In our HBC clinic, we observed that our rate of positive results is comparable, yet at the higher end of the range which is reported in other populations. The importance of expanded, multi-gene panel testing is highlighted by the fact that almost half of the patients had pathogenic or likely pathogenic variants in genes other than BRCA1/2, and that our test positivity rate would have only been 12.8% if only BRCA1/2 testing was done. As the database expands and protocol-driven referrals are made across the country, our insight about the genetic architecture of HBC in our population will continue to increase.


  • Open Access

    Difficulty Breathing or Just a Case of the Nerves? Incidental Finding of Primary Pleural Schwannoma in a COVID-19 Survivor

    by Daania Shoaib, Muhammad N. Zahir, Saqib R. Khan, Adnan A Jabbar, Yasmin A Rashid

    Schwannoma is a rare tumor that arises from the Schwann cells, which are specialized, myelin-producing cells of the peripheral nerve sheaths. As anatomic logic would dictate, these masses commonly occur in the skull base, cerebellopontine angle, and posterior spinal roots. Of this already rare entity, rarer still are the pleural schwannomas, representing approximately 1-2% of thoracic tumors. These tumors commonly affect adults with a propensity for the third and sixth decades of life and a comparative male predilection. Schwannomas are benign, indolent, and follow an asymptomatic course. As such, they often come to light incidentally. Here we report a case of primary pleural schwannomas in a 68-year-old female, found incidentally on a CT scan of the chest. To the best of our knowledge and literature review, no other similar case has been reported in our country, Pakistan. Around three weeks before her presentation, she was diagnosed with COVID-19. Her infection had run a mild course with quick recovery without the need for any hospitalization. Therefore, the manifestation of shortness of breath after resolution of all other symptoms prompted a further workup. Radiographic chest x-ray revealed an incidental finding of a large right upper lobe lung mass, slightly impinging on the trachea. This was followed by a chest CT scan at our radiological imaging facility, which showed a large, well-encapsulated, right upper lobe lung mass in the paraspinal apical location. She then underwent an image-guided biopsy of the aforementioned mass, pathological analysis of which was suggestive of a benign peripheral nerve sheath tumor (PNST) arising from the pleura (pleural schwannoma). She underwent right posterolateral thoracotomy with uneventful complete surgical removal of the pleural-based lung mass. Postoperative investigations included a chest x-ray that showed interval complete resection of the mass. Currently, she is asymptomatic and her clinical condition has improved with the successful resumption of her daily routine. Physicians thus need to keep pleural schwannomas in mind as a probable diagnosis of intrathoracic tumors. Indolent and asymptomatic, they are very amenable to surgical resection with little to no chances of recurrence in the long term. However, these patients should be closely followed with repeat imaging studies when symptomatic.


  • Open Access

    Capecitabine-Associated Loss of Fingerprints: A Case Report of a 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia

    by Tasneem Dawood, Muhammad Nauman Zahir, Muhammad Afzal, Yasmin Abdul Rashid

    Background: Capecitabine is a prodrug of 5-fluorouracil (5-FU) and is converted to 5-FU in tumor tissue. Its primary mechanism of action is the suppression of DNA synthesis via inhibition of thymidylate synthetase. It is mostly used for neoadjuvant chemoradiation, adjuvant chemotherapy for colorectal cancer, metastatic breast, and localized and metastatic gastric cancer, among others. Adverse effects of capecitabine include diarrhea, hand-foot syndrome (HFS), pancytopenia, stomatitis, increased bilirubin, nausea, vomiting, and very rarely adermatoglyphia. Dermatoglyphics refers to fingerprints. Adermatoglyphia refers to the loss of fingerprints. Case review summary: We report the case of a 62-year-old male patient known case of locally advanced colorectal cancer. He presented in the clinic with residual disease after initially being treated with local surgery and chemoradiation with 5-FU. Positron emission tomography (PET) scan done at the time of presentation showed locally advanced disease. He was managed with surgery followed by chemotherapy with oxaliplatin 130 mg/m2 and capecitabine (Xeloda) 1500 mg twice a day for two weeks via three weekly cycles. Post cycle five, the patient complained of grade I HFS symptoms and inability to open a bank account due to loss of fingerprints. The patient was oblivious about this condition before that. After completing his adjuvant treatment that is six cycles of oxaliplatin and Xeloda, his symptoms of the HFS and loss of fingerprints, improved. Conclusion: As this case describes, adermatoglypia is a rare but noticeably side effect of capecitabine with a high chance of reversibility. Similar case reports have been reported with some normalization of fingerprints, after stopping treatment. Fingerprints have been used for centuries as means of identification in banks, aviation, immigration, computers, and mobile phones, amongst others. Awareness regarding the loss of fingerprints due to capecitabine is important for the patient and clinician, and alternative means of identification or other adaptive methods of recognition should be used for these patients.